Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

NCT05291091 is registered in ClinicalTrials.gov with Edgewise Therapeutics, Inc. as lead sponsor.

NCT NCT05291091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05291091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy
Lead sponsor
Edgewise Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2022
Completion date
September 7, 2026
Enrollment
244 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

becker muscular dystrophy